BioAge Labs (NASDAQ:BIOA) Sets New 12-Month High – What’s Next?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $24.42 and last traded at $24.5980, with a volume of 180857 shares. The stock had previously closed at $22.83.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BIOA shares. BTIG Research began coverage on BioAge Labs in a report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target on the stock. Citigroup upped their price objective on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Oppenheimer assumed coverage on BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target on the stock. Finally, Wall Street Zen downgraded BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

BioAge Labs Trading Up 0.8%

The company’s fifty day moving average is $17.79 and its 200 day moving average is $17.75. The company has a market capitalization of $1.02 billion, a P/E ratio of -9.54 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.19. The company had revenue of $2.77 million during the quarter. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%. Equities research analysts predict that BioAge Labs, Inc. will post -2.68 EPS for the current year.

Institutional Trading of BioAge Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC boosted its stake in BioAge Labs by 411.8% during the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock valued at $36,597,000 after buying an additional 1,685,063 shares during the period. Octagon Capital Advisors LP raised its stake in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock valued at $30,573,000 after purchasing an additional 150,000 shares in the last quarter. Vanguard Group Inc. lifted its position in BioAge Labs by 6.0% during the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after purchasing an additional 93,694 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in BioAge Labs during the fourth quarter valued at approximately $13,892,000. Finally, Geode Capital Management LLC grew its stake in BioAge Labs by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 591,377 shares of the company’s stock worth $7,826,000 after buying an additional 28,646 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.